Compare AMTX & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMTX | ANEB |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.0M | 96.8M |
| IPO Year | N/A | 2021 |
| Metric | AMTX | ANEB |
|---|---|---|
| Price | $1.36 | $1.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 760.7K | 102.1K |
| Earning Date | 11-06-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $201,323,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $139.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.22 | $0.90 |
| 52 Week High | $3.66 | $3.42 |
| Indicator | AMTX | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 33.84 | 18.73 |
| Support Level | $1.34 | $1.14 |
| Resistance Level | $1.61 | $2.40 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 7.41 | 4.23 |
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.